Hepatitis C News and Research

Latest Hepatitis C News and Research

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

BIOVISION's 10th edition to focus on today’s health challenges

BIOVISION, the annual life sciences forum organized by the Foundation for the University of Lyon, today announces its 10thedition, which will take place on April 15 and 16, 2015 at the Musée des Confluences in Lyon, France.

6 Nov 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

MinuteClinic enters into clinical collaboration agreement with Lifespan

MinuteClinic, the retail medical clinic of CVS Health, and Lifespan, Rhode Island's largest health system, which includes five partner hospitals and multiple physician groups, announced today that they have entered into a clinical collaboration agreement.

27 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

Few California inmates with hepatitis C get costly Sovaldi

In San Francisco's jails, no inmates with hepatitis C are receiving Sovaldi, the breakthrough pill that can cure most patients in an unprecedented amount of time.

21 Oct 2014

Newly developed agent filters out toxins from body in the event of overdose

Every minute counts in the event of an overdose. ETH professor Jean-Christophe Leroux and his team have developed an agent to filter out toxins from the body more quickly and efficiently.

17 Oct 2014

Foreign-born residents with low vaccination rates face greater risk of exposure to diseases

Foreign-born residents with low vaccination rates and their relatives in the U.S. are at greater risk of exposure to several vaccine-preventable diseases, e.g. influenza; pneumococcal diseases; tetanus, diphtheria and pertussis; hepatitis A; hepatitis B; shingles; and HPV, the human papilloma virus, which can lead to some types of cancer.

16 Oct 2014

State highlights: Supreme Court to hear N.C. scope-of-practice case; states weigh costs of new hepatitis C drugs

The Supreme Court on Tuesday will consider who can whiten teeth in North Carolina, a seemingly small decision that could have major implications for scope-of-practice throughout the country. In North Carolina Board of Dental Examiners v. Federal Trade Commission, the justices will weigh whether the state dental board's decisions - in this case, a decision to not allow anyone but a dentist to whiten teeth - are immune from antitrust protections typically granted to state agencies (Haberkorn, 10/13).

15 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

FDA approves new hepatitis C drug, Harvoni

Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients.

14 Oct 2014

Molecular diagnostics and blood screening systems: an interview with Dr Bos and Dr Koppelman

Screening blood donations and molecular diagnostics for patients started in the nineties. At the beginning, the level of automation in molecular diagnostic testing was limited; most of the work had to be done manually.

12 Oct 2014

European experts publish common vision of priorities for marine research

Some 340 European scientists, policy-makers and other experts representing 143 organizations from 31 countries spoke with one voice today, publishing a common vision of today's most pressing marine-related health and economic threats and opportunities.

9 Oct 2014

Columbia Nursing researcher suggests ways to prevent nursing home infections

Nursing home infection rates are on the rise, a study from Columbia University School of Nursing found, suggesting that more must be done to protect residents of these facilities from preventable complications. The study, which examined infections in U.S. nursing homes over a five-year period, found increased infection rates for pneumonia, urinary tract infections (UTIs), viral hepatitis, septicemia, wound infections, and multiple drug-resistant organisms (MDROs).

8 Oct 2014

Revolutionary Hypo-tec Needlestick Injury Prevention Product enters North American market

V3 Healthcare Strategies, a Wisconsin-based Accountable Care Strategies company, announced the North American launch of the revolutionary Hypo-tec Needlestick Injury Prevention Product amidst an environment of infectious catastrophic diseases such as Ebola, Hanta & Hemorrhagic Fevers, while simultaneously protecting against all other infectious diseases such as HIV/AIDS, Hepatitis and more.

8 Oct 2014

State highlights: States and drug prices; Ariz. limiting Sovaldi for patients; L.A. boosts uninsured care by $61 million

Because of its high cost, some state Medicaid programs and prison systems are refusing to provide Sovaldi to any but the sickest patients. Most recently, Oregon last month threatened to limit access to the drug unless it can get Sovaldi at a deeply discounted price. But Sovaldi is only the beginning. Expensive new treatments for certain cancers, rheumatoid arthritis and other conditions also have rattled Medicaid officials, patients and health care providers. What can states do to hold down drug costs? Drug pricing is a complicated and opaque process.

8 Oct 2014

Seven NIH research contracts awarded to identify novel adjuvant candidates

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.

30 Sep 2014

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd.

29 Sep 2014

Study correlates HPV vaccine series completion among young US women

According to a recent study in the journal Human Vaccines & Immunotherapeutics, only 60% of young US women who received the first dose of the human papilloma virus (HPV) vaccine went on to complete the three-dose vaccine series.

29 Sep 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Johnson & Johnson completes acquisition of Alios BioPharma

BIOVISION's 10th edition to focus on today’s health challenges

NCI supports further clinical development of next-generation HPV vaccine

MinuteClinic enters into clinical collaboration agreement with Lifespan

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Few California inmates with hepatitis C get costly Sovaldi

Newly developed agent filters out toxins from body in the event of overdose

Foreign-born residents with low vaccination rates face greater risk of exposure to diseases

State highlights: Supreme Court to hear N.C. scope-of-practice case; states weigh costs of new hepatitis C drugs

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

FDA approves new hepatitis C drug, Harvoni

Molecular diagnostics and blood screening systems: an interview with Dr Bos and Dr Koppelman

European experts publish common vision of priorities for marine research

Columbia Nursing researcher suggests ways to prevent nursing home infections

Revolutionary Hypo-tec Needlestick Injury Prevention Product enters North American market

State highlights: States and drug prices; Ariz. limiting Sovaldi for patients; L.A. boosts uninsured care by $61 million

Seven NIH research contracts awarded to identify novel adjuvant candidates

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Study correlates HPV vaccine series completion among young US women

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in